AIM
AIM ImmunoTech Inc.·Healthcare
0.49
108.423%(+0.25)
Market OpenLast Updated: — ET
52W L: $0.2152W H: $19.74
AIM NEWS
globenewswire.com
7h ago
AIM ImmunoTech Announces Emerging Ebola Opportunity for Ampligen Amid Escalating Global Health Concerns and WHO Emergency Declaration
Previously published Biosafety Level 4 pre-clinical study showed 100% survival with early treatment following infection in a mouse model following lethal doses of Ebola
proactiveinvestors.co.uk
5d ago
Creo Medical Group to raise £5.5m and advance partial divestment
Creo Medical Group PLC (AIM:CREO, FRA:1RC, OTC:CMEOF) announced plans to raise approximately £5.5 million through a placing as the medical device company moves to strengthen its balance sheet while pursuing the sale of its remaining stake in Creo Medical Europe. The AIM-listed group said it intends to issue around 36.7 million new shares at 15p each, a 31.9% premium to Thursday's closing mid-market price of 11.4p.
globenewswire.com
May 20
AIM ImmunoTech Announces $2.4 Million Financing, Including Concurrent Registered Direct Offering and Private Placement
OCALA, Fla. , May 20, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company", today announced that it has entered into definitive agreements for a registered direct offering priced at-the-market under NYSE Rules of an aggregate of 7,519,351 shares of common stock, par value $0.
globenewswire.com
May 20
AIM ImmunoTech Announces $2.4 Million Financing, Including Concurrent Registered Direct Offering and Private Placement
OCALA, Fla., May 20, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc . (NYSE American: AIM) (“AIM” or the “Company”, today announced that it has entered into definitive agreements for a registered direct offering priced at-the-market under NYSE Rules of an aggregate of 7,519,351 shares of common stock, par value $0.001 per share (the “Common Stock”) (or common stock equivalents in lieu thereof) at a purchase price of $0.325 per share. The gross proceeds to the Company from the offering are expected to be approximately $2.4 million, before deducting placement agent commissions and other offering expenses. In addition, in a concurrent private placement, the Company will issue and sell unregistered Series I warrants (the “Series I Warrants”) to purchase up to 15,038,702 shares of Common Stock. The Series I Warrants will have an exercise price of $0.325 per share, will be exercisable subject to stockholder approval and will expire five (5) years from the initial exercise date.
proactiveinvestors.co.uk
May 20
88 Energy says Augusta-1 exploration well is on track for Q1 2027
88 Energy Ltd (AIM:88E, ASX:88E, OTCQB:EEENF, FRA:POQ) has told investors that its planned Augusta-1 exploration well at South Prudhoe on Alaska's North Slope remains on track for a first-quarter 2027 spud, as the company advances permitting, logistics and farm-out discussions. The AIM and ASX-listed explorer said Augusta-1 is designed to test up to 133.7 million barrels of gross unrisked 2U prospective resources, or 111.4 million barrels net to 88 Energy, across stacked Ivishak, Kuparuk and Brookian reservoir targets.
businesswire.com
May 19
CMMI Institute Completes Pilot for New AI Maturity (AIM) Framework
SCHAUMBURG, Ill.--(BUSINESS WIRE)-- #isaca--CMMI Institute, a global leader in helping organizations reduce risk, boost performance, and build capability, is now extending this guidance to artificial intelligence, and has recently completed a pilot program for its new AI Maturity (AIM) framework. AIM enables organizations to assess, benchmark and improve how AI is implemented across real-world enterprise and regulatory environments, linking AI practices and governance to measurable, scalable outcomes. T.
